ArticleImmunity, inflammation and disease2025
Cordyceps sinensis (CS) Alleviates Chronic Obstructive Pulmonary Disease Symptoms (COPD) by Targeting Inflammation, Apoptosis, and Oxidative Stress Through Ingredient-Gene-Disease Interaction.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-pathway targeting by natural products in chronic respiratory diseases: Opportunities, challenges, and future perspectives.Chinese herbal medicines · 2026Article
- The integrated analysis of PRDX3 in lung cancer: biomarker potential and therapeutic target prospects.Respiratory research · 2026Article
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
- Cordyceps sinensis (CS) Alleviates Chronic Obstructive Pulmonary Disease Symptoms (COPD) by Targeting Inflammation, Apoptosis, and Oxidative Stress Through Ingredient-Gene-Disease Interaction.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveCordyceps sinensis (CS) is a fungus that parasitizes the larvae and corpses of Batmadaceae insects. CS is used as a traditional Chinese medicine and has shown promising clinical efficacy in the treatment of chronic obstructive pulmonary disease (COPD). This study aimed to identify potential targets of CS in the treatment of COPD and to analyse the related biological processes and signalling pathways.
methodsThrough the use of network pharmacological tools, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, as well as corroborating data from Gene Expression Omnibus (GEO) and the literature, potential targets for CS treatment of COPD were identified and analysed.
resultsThese results suggest that CS alleviates COPD symptoms with key biomarkers such as interleukins (ILs), tumour necrosis factor (TNF), and reactive oxygen species (ROS). The primary active constituents of CS comprise Cordycepin, D-mannitol, Ergosterol, Cordyceps polysaccharides, and others. During the pathogenesis of COPD, CS exerts modulates effects on various proteins and signalling pathways, influencing gene expression patterns such as poly ADP-ribose polymerase 1 (PARP1), phosphodiesterase 4A (PDE4A), phosphodiesterase 4B (PDE4B), phosphodiesterase 4C (PDE4C), phosphodiesterase 4D (PDE4D), prostaglandin D2 receptor 2 (PTGDR2), heme oxygenase 1 (HMOX1), and matrix metallopeptidase 1 (MMP1).
conclusionCS alleviates COPD symptoms by suppressing inflammation, apoptosis, and oxidative stress, suggesting novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.